Geron Announces New Data To Be Presented Highlighting The Potential Of RYTELO In Myeloid Hematologic Malignancies At Upcoming ASH Annual Meeting
Geron Announces New Data To Be Presented Highlighting The Potential Of RYTELO In Myeloid Hematologic Malignancies At Upcoming ASH Annual Meeting
傑龍宣佈將在即將召開的ASH年會上發佈RYTELO在骨髓血液惡性腫瘤中潛力的新數據。
- New analyses from the IMerge clinical trial suggest that imetelstat demonstrates clinical activity in patients with lower-risk MDS with transfusion-dependent anemia regardless of prior therapy
- Early safety results from the dose escalation phase of the Phase 1 IMproveMF study suggest potential for the tolerability of combination therapy with imetelstat and ruxolitinib in a frontline myelofibrosis patient population
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the publication of abstracts containing new data highlighting the potential of RYTELO (imetelstat), a first-in-class telomerase inhibitor, in myeloid hematologic malignancies. Six abstracts have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting taking place from December 7-10, 2024, in San Diego, California and virtually.
資訊熱榜
更新時間